Skip to content
Screener

Immunovant, Inc. IMVT United Kingdom — Total loss before income taxes

Other geography segments

Switzerland
-$606.29M-53.4%
United States
$100.99M+670%
Bermuda
-$39K+61.0%

Similar metrics at other companies

Mirion Technologies logo
MIRUnited States — Income (loss) before income taxes
-$3.8M+78.8%
Roivant Sciences logo
ROIVUnited States — Total (loss) income from continuing operations before income taxes
-8,862,725,000%-319,694,836,012pp
Incyte logo
INCYUnited States — Income before provision for income taxes
$392.94M+291%
Mirion Technologies logo
MIRForeign — Income (loss) before income taxes
$11.98M+26.4%
Q2 Holdings logo
QTWOU.S. — Income (loss) before income taxes
$11.57M+220%
Citizens logo
CIAUnited States — Income (loss) before income tax expense
$1.86M+272%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemYears Ended March 31, 2026Years Ended March 31, 2025Years Ended March 31, 2024
United States$100,991$(17,730)$(16,180)
Switzerland(606,288)(395,119)(242,518)
Bermuda(39)(100)(71)
United Kingdom(55)
Total loss before income taxes$(505,391)$(412,949)$(258,769)
Current taxes
United States – Federal$880$562
United States – State215115

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s united kingdom — total loss before income taxes?
Immunovant, Inc. (IMVT) reported united kingdom — total loss before income taxes of -$13.75K in Q1 2026.
What is the long-term trend for Immunovant, Inc.'s united kingdom — total loss before income taxes?
Over 4 years (2022 to 2026), Immunovant, Inc.'s united kingdom — total loss before income taxes has grown at a 129.0% compound annual growth rate (CAGR), from -$2K to -$55K.
What does united kingdom — total loss before income taxes mean?
This metric represents the pre-tax financial loss generated specifically by operations within the United Kingdom geographic segment. It reflects the net result of revenues and expenses incurred in this region before accounting for income tax provisions. Monitoring this figure helps investors assess the regional profitability profile and the burn rate associated with international clinical development or administrative activities.

Ask your AI about Immunovant, Inc.'s united kingdom — total loss before income taxes.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude